Update on our RAMP 203 trial with Amgen: We're evaluating investigational combo of avutometinib + sotorasib +/- defactinib in KRAS G12C mutant NSCLC. Preliminary data on the triplet combo looks encouraging. We look forward to sharing more at a medical meeting in 2H 2025. $VSTM

The FDA has accepted and granted Priority Review to our NDA for our investigational combination of avutometinib and defactinib for the treatment of recurrent KRAS mutant Low-Grade Serous Ovarian Cancer. Read more: investor.verastem.com/news-releases/… $VSTM #LGSOC

Today, we announced a new credit facility and equity investment with Oberland Capital and a strategic commercialization collaboration with @IQVIA_Global $VSTM #LGSOC

Today, we announced that we have exercised our option early to license VS-7375, a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor currently in Phase 1 development in China by partner GenFleet Therapeutics. $VSTM #G12D #KRAS

Today, we shared our 2025 outline of strategic priorities and milestones for our novel pipeline, with hopes to advance new medicines for patients with RAS/MAPK pathway-driven cancers. $VSTM

On February 5th, we’ll be participating in the Guggenheim SMID Cap Biotech Conference. A live webcast of our session will be available on our website. $VSTM

Don’t miss our multiple oral and poster presentations at this year’s SGO Annual Meeting on Women’s Cancer. See you there! #MultiplyYourImpact #SGO25 $VSTM

At #ASCO25, we will be sharing updated data from RAMP 205, our first-line metastatic #pancreaticcancer study. The abstract is under embargo until May 22 and we will be reporting additional data at that time.​ $VSTM

Our management team will be participating in multiple investor conferences this month. Read our press release to learn about the events and webcast details: investor.verastem.com/news-releases/… $VSTM

Today, we announced our Q1 2025 financial results and latest business updates. Read our press release to learn more about our recent FDA approval, steps taken to strengthen our balance sheet, and how we have advanced our novel, potential best-in-class G12D clinical program. $VSTM

Today, we announced positive updated results from our RAMP 205 clinical trial in first-line metastatic #pancreaticcancer. Read our release to learn more: investor.verastem.com/news-releases/… $VSTM #ASCO25

At #ASCO25, we will be hosting an R&D investor webcast to review RAMP 205 and updated data from the VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, study in China by partner GenFleet Therapeutics. Read our press release to learn more: investor.verastem.com/news-releases/… #VSTM

#BreakingNews – Our partner GenFleet Therapeutics presented updated data this morning at #ASCO25 for their study of GFH375 (VSH-7375), an oral #KRAS #G12D (ON/OFF) inhibitor. Read more: investor.verastem.com/news-releases/… $VSTM

Our management team will be participating in a fireside chat at Jefferies Global Healthcare Conference tomorrow. We will recap our latest data updates from #ASCO25 and discuss our future clinical development plans. $VSTM

Today, we announced the dosing of the first patient with VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in the U.S. ​ #VerastemOnc #G12D #KRAS $VSTM

The FRAME trial, the first-in-human study to evaluate avutometinib in combination with defactinib in patients with LGSOC, was recently published in Nature Medicine . Read about the updated results here: link to PR $VSTM #LGSOC #cancerresearch #KRAS

Today, we shared that the primary analysis from the Phase 2 RAMP 201 clinical trial has now been published in the Journal of Clinical Oncology. ​ Read more about the publication here: investor.verastem.com/news-releases/…​ ​$VSTM #KRAS #LGOSC

Today, we announced that we have received Fast Track Designation from the FDA for VS-7375, our investigational KRAS G12D (ON/OFF) inhibitor, for the treatment of 1L & 2L locally advanced or metastatic #pancreaticcancer. investor.verastem.com/news-releases/… $VSTM #KRAS

Today, we announced that we will be holding our Q2 earnings call on Thursday, August 7, at 4:30 pm ET. Read more: investor.verastem.com/news-releases/… $VSTM